Screener
Agios Pharmaceuticals AGIO Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling, general and administrative | 51,547 | 45,869 | 99,851 | 87,396 |
| Total operating expenses | 155,297 | 139,511 | 286,068 | 254,866 |
| Loss from operations | (110,552) | (127,056) | (220,577) | (233,685) |
| Interest income, net | 9,730 | 14,513 | 20,525 | 30,600 |
| Other income, net | 119 | 523 | 238 | 1,776 |
| Net loss | $(100,703) | $(112,020) | $(199,814) | $(201,309) |
| Net loss per share - basic and diluted | $(1.69) | $(1.93) | $(3.38) | $(3.49) |
| Weighted-average number of common shares used in computing net loss per share – basic and diluted | 59,488,871 | 57,932,576 | 59,137,508 | 57,697,193 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's business segments — net loss?
- Agios Pharmaceuticals (AGIO) reported business segments — net loss of -$100.7M in Q2 2026.
- How has Agios Pharmaceuticals's business segments — net loss changed year-over-year?
- Agios Pharmaceuticals's business segments — net loss increased by 10.1% year-over-year, from -$112.02M to -$100.7M.
- What is the long-term trend for Agios Pharmaceuticals's business segments — net loss?
- Over 2 years (2022 to 2025), Agios Pharmaceuticals's business segments — net loss has grown at a 33.4% compound annual growth rate (CAGR), from -$231.8M to -$412.78M.
- What does business segments — net loss mean?
- This metric represents the net financial result for the reportable segment after accounting for all revenues, gains, and operating expenses. It indicates whether the segment is currently generating a profit or operating at a loss during the reporting period. This is a primary indicator of the segment's financial health and its contribution to the company's overall profitability.
Ask your AI about Agios Pharmaceuticals's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude